Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,561 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer (NSCLC) Clear all
Completed Phase 2 Interventional Results available

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

NCT00098254
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
BAY 43-9006 (Sorafenib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 18, 2026, 9:25 AM EDT
Withdrawn Phase 2 Interventional

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

NCT04989283
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
46
States / cities
Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting Phase 2Phase 3 Interventional

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

NCT03851445
View directory record Official record
Conditions
Previously Treated Non-Small Cell Lung Cancer
Interventions
Screening Platform
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1229
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Harvesting Cells for Experimental Cancer Treatments

NCT00068003
View directory record Official record
Conditions
Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
Anti-CD19 CAR PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Terminated Early Phase 1 Interventional

Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

NCT01525446
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
SBRT with proton beam radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

NCT05777603
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
aerosolized aztreonam, aerosolized vancomycin, pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Active, not recruiting Phase 1 Interventional

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

NCT03824327
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy
Procedure · Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting No phase listed Observational

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting Phase 1 Interventional

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
FT836, Cetuximab, Trastuzumab
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Not applicable Interventional

Computer-Assisted Counseling in Helping African American Smokers Stop Smoking

NCT00310141
View directory record Official record
Conditions
Lung Cancer
Interventions
Smoking cessation intervention, Counseling intervention, Nicotine patch
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 18, 2026, 9:25 AM EDT
Terminated Phase 1 Interventional

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00369551
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis
Radiation · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Phase 2 Interventional

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00068653
View directory record Official record
Conditions
Lung Cancer
Interventions
Celecoxib, ZD1839
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Phase 2 Interventional

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

NCT06348888
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Itraconazole, Carbamazepine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 18, 2026, 9:25 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882
View directory record Official record
Conditions
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Docetaxel, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

NCT01721759
View directory record Official record
Conditions
Squamous Cell Non-small Cell Lung Cancer
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 18, 2026, 9:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Terminated Phase 1 Interventional

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

NCT00049608
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions
mistletoe extract, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 18, 2026, 9:25 AM EDT
Recruiting Phase 2 Interventional

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01639508
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Completed Not applicable Interventional Results available

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

NCT00832780
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Solid Tumors
Interventions
Stereotactic Body Radiation
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 18, 2026, 9:25 AM EDT
Terminated Phase 2 Interventional Results available

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

NCT05846646
View directory record Official record
Conditions
Oligometastatic Disease
Interventions
IMSA101, Immune checkpoint inhibitor, PULSAR
Drug · Radiation
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Irvine, California • Kansas City, Kansas • New Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 18, 2026, 9:25 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-927, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 18, 2026, 9:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 18, 2026, 9:25 AM EDT